⭐️ Check out our new pub in @Gut_BMJ Epidemiology of GI Cancer 3.70 million deaths from GI cancer 📈 Colorectal & pancreatic cancer 📉 Overall liver cancer 📈 Liver cancer from #MASLD & #ALD https://t.co/1RLiHRQKp9 #GITwitter @KarnJUVE @JuDongYang1 @RashidLui @LewisRobertsMD

New review - Age-related changes of the gastrointestinal tract https://t.co/wBq1ym455M #GITwitter #MedTwitter

#LiverTwitter Our new study published in APT! where "Less than 10% of patients received the recommended biannual ultrasound scans for surveillance."😱 https://t.co/WhL5TDQq9j @KarnJUVE @nogamia_liver @DrHuangDQ @DrMarkMuthiah @PojsakornDan

#LiverTwitter Read our new meta-analysis in CGH: Patients with MASLD + advanced fibrosis face a real risk of HCC, even without cirrhosis. 📈 Incidence climbs from ~0.8% at 1 yr → ~9% at 10 yrs. 🔗 https://t.co/CkBnITxvM2

Any daily alcohol consumption is associated with certain cancers, and the risk of cancer increases with higher alcohol intake. This JAMA Insights discusses the evidence related to the US Surgeon General’s Advisory on alcohol and cancer risk. https://t.co/PAGkysHfA2

Check out our new article in @CMH_journal 🇺🇸 SLD prevalence: 35.0% ⚠️During COVID, SLD prevalence stable, advanced fibrosis rose significantly 📈 ❗ALD cases had 2× more advanced fibrosis and cirrhosis than MASLD/MetALD 🔗 https://t.co/qk40YB6x03 @KarnJUVE #GITwitter

🌟 Congrats to our 2025 #AASLDFoundation #EmergingLiverScholars: 👏 @darinedaher – @MayoClinic Rochester 👏 @PojsakornDan – @ttuhscmed 👏 Sandra Elmasry – @MayoClinic Arizona 👏 @ClaireSFaulkner – @BMCimRES View the full list: https://t.co/spYSpZhaBl

Our commentary is now available on @LancetRH_WPac Multisystem burden in cirrhosis: lessons from a marginalised population https://t.co/QeA2Nw3Dg8 @docamitgs @JVLazarus

Register for today’s ACG Virtual Grand Rounds: Dr. Ashwani Singal on Prevention of Alcohol-Associated Liver Disease! ⏰ Noon & 8 pm ET ➡️ https://t.co/9t8dHChSZw @singal_ashwani @BlaneyMD

@ChawinthornV @TexasTech @oncodaily

Thank you @IUGastro and @l_suthat for highlighting our study in @amjmed 📊 1.12M GI cancer deaths were linked to modifiable risks ⚠️ Top culprits: Metabolic risk 🌍 Developing countries were disproportionately affected @KarnJUVE @JuDongYang1 @l_suthat @docamitgs @NoureddinMD

Magic Numbers in Hepatology ▪️MAP goal >82 in outpts ▪️Plt <160 = concern ▪️Spleen ≥12 cm ➡️ portal HTN ▪️Portal v ≥13 mm ➡️ portal HTN ▪️SAAG ×10 ≈ HVPG (1.1=11) ▪️TIPS safe for ascites if MELD-Na ≤18 ▪️MELD-Na >15 ➡️ refer for transplant ▪️“6-month sobriety rule” = outdated

🔥 Check out our review in @BMJOpen_Gastro 🧠 AI is changing HCC surveillance. 🖥️ Deep learning boosts detection 🔬 Integrating labs + imaging = smarter risk stratification. https://t.co/hmXqfZFasY @Apichatka @wisit661

#CGH4ALL new @AGA_CGH article reports ⏫ incidence of MASLD & MASH globally🌎 Correlated with ⏫ burden of primary liver cancer Unfortunately Americas are leading the race🛑‼️ 🔗 https://t.co/MX09f0iCUU @PojsakornDan @AbdoMattia @thanathip_ham @JerapasT @DrHuangDQ

📖 Retrospective cohort study on neighborhood SDOH in MASLD hot off the press! 📖 🚩Patients w/ MASLD living in the most disadvantaged neighborhoods have ⬆️ mortality, liver dz burden, 🫀 disease & T2DM. Now in @AGA_CGH ! 🔗 https://t.co/yoV3emPtzj Thank you to my mentor @KarnJUVE

Honored that our study was highlighted by Dr. Nath, Editor-in-Chief, in the July issue of @MayoProceedings. Grateful for the recognition and continued support of our work 🙏📘 https://t.co/K9w6TO1f9t @KarnJUVE @RashidLui @NoureddinMD @JuDongYang1 @Omar_Mousa85

📢 New in @GIE_Journal ! Our meta-analysis (5,753 patients) shows that covered metal stents led to: 🔺 higher risk of post-ERCP cholecystitis 🔺 higher stent migration 🔻 lower tumor ingrowth 🔗 https://t.co/AeTFcGOZUL

So honored for our meta-analysis to be featured in Dr. Adler, Editor-In-Chief’s note in the lastest issue @GIE_Journal @DouglasAdlerMD 🙏🏼 Check out the beautiful graphical abstract for a quick take-away! 🔗: https://t.co/UhNUqbPpKG

Two key points that we need to remember about the new SLD (Steatotic Liver Disease) nomenclature: 1️⃣ SLD ≠ MASLD — it also includes Alcohol-Related Liver Disease (ALD). 2️⃣ A person with metabolic syndrome + 10 drinks/day has ALD, not MetALD. @AASLDtweets @EASLedu @AEEHLiver

In today’s #readoftheweek📚 from @karolinskainst, learn how paediatric obesity enhances the risk in individuals who had alcohol use disorders during adolescence or young adulthood. Read here this @JHEP_Reports article: https://t.co/pjWmKDtZZT #LiverX #LiverTwitter

After a heart attack, people with liver disease are amongst the least likely to receive guideline directed therapies Sad Spread the word: statins are ok in liver disease